Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

This double-blinded stratified placebo-controlled randomized clinical trial compared adaptive treatment with standard treatment for smoking cessation.

Participants were allowed to choose varenicline or nicotine patches and were then randomized to adaptive or nonadaptive (standard) treatment.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

The study was conducted at a university health system in Durham, North Carolina, from February 2018 to May 2020 and was stopped early due to COVID-19.

Data were analyzed as intent-to-treat from May 24, 2021, to February 27, 2022.

Participants started on their chosen medication (adaptive) or placebo (standard) 4 weeks before their target quit day.

Two weeks later, participants were assessed for treatment response.

Participants in the standard treatment group received varenicline starting 1 week before the target quit date or nicotine patches starting on the target quit day.

What Was Measured

The subject headings attached to it are Smoking Cessation, Varenicline, Bupropion, Nicotine, Pandemics, COVID-19 and Tobacco Use Cessation Devices.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (JAMA network open), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.